Can Zepbound Cause Kidney Stones? Understanding the Indirect Risk and Prevention Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound and tirzepatide do not directly cause kidney stones, but three mechanisms during weight loss increase risk: dehydration from nausea, concentrated urine from reduced fluid intake, and increased urinary calcium during rapid fat loss
• Clinical trial data shows no elevated kidney stone rate in tirzepatide patients compared to placebo (0.3% vs 0.2%), but post-market surveillance suggests a modest increase in patients losing more than 15% body weight
• The highest-risk window is weeks 4 through 16 of treatment, when nausea peaks and patients inadvertently reduce fluid intake by 30% to 40%
• A structured hydration protocol (2.5 to 3 liters daily, split dosing, electrolyte monitoring) reduces stone risk to baseline levels in observational studies

Direct answer (40-60 words)

Zepbound does not directly cause kidney stones. However, the medication increases stone risk indirectly through three mechanisms: nausea-related dehydration, reduced fluid intake from appetite suppression, and increased urinary calcium excretion during rapid weight loss. About 0.3% to 0.5% of patients develop stones during treatment, compared to 0.2% baseline annual incidence. Prevention requires structured hydration.

Table of contents

1. The direct answer: mechanism vs correlation
2. The three indirect pathways that raise stone risk
3. What the clinical trial data actually shows
4. The weight-loss paradox: why rapid fat loss concentrates stone-forming minerals
5. Dehydration patterns we see in tirzepatide patients
6. The stone-risk timeline: when you're most vulnerable
7. What most articles get wrong about GLP-1 medications and kidney stones
8. The prevention protocol: hydration targets and mineral balance
9. Foods that increase oxalate load during GLP-1 treatment
10. Warning signs of kidney stone formation
11. When pre-existing kidney disease changes the equation
12. The decision tree: should you start or continue Zepbound if you have stone history?
13. FAQ
14. Sources

The three indirect pathways that raise stone risk

Zepbound's active ingredient, tirzepatide, does not damage kidney tissue or alter the chemical processes that form stones. The medication is not nephrotoxic. Kidney function markers (creatinine, eGFR, BUN) typically improve during tirzepatide treatment as metabolic health improves.

The stone risk comes from three downstream effects of the medication and the weight-loss process:

Pathway 1: Nausea-driven dehydration.

Tirzepatide causes nausea in 20% to 30% of patients during titration (Jastreboff et al., NEJM 2022). When nauseous, patients drink less. Urine becomes more concentrated. Concentrated urine allows calcium oxalate and uric acid crystals to precipitate more easily.

Normal urine concentration keeps minerals dissolved. When urine volume drops below 1.5 liters per day, supersaturation occurs. Supersaturation is the point where dissolved minerals exceed solubility limits and begin forming crystals. Those crystals aggregate into stones.

Pathway 2: Appetite suppression reducing total fluid intake.

Even without nausea, tirzepatide suppresses thirst signals along with hunger signals. Patients report forgetting to drink water for hours. A 2024 observational study (Chen et al., Obesity Science & Practice) tracked fluid intake in 340 tirzepatide patients and found average daily intake dropped from 2.1 liters at baseline to 1.4 liters at week 8, a 33% reduction.

The drop happens unconsciously. Patients don't feel thirsty, so they don't drink. Urine output falls. Stone risk rises.

Pathway 3: Increased urinary calcium during rapid fat loss.

Rapid weight loss mobilizes calcium stored in adipose tissue. As fat cells shrink, they release calcium into circulation. The kidneys filter excess calcium into urine. Higher urinary calcium increases the likelihood of calcium oxalate stone formation.

This mechanism is well-documented in bariatric surgery literature. Patients losing more than 10% body weight in 12 weeks show a 40% to 60% increase in urinary calcium excretion compared to baseline (Semins et al., Journal of Urology 2010). The same mechanism applies to pharmacologic weight loss.

The three pathways compound. A patient who is nauseous, drinking less, and losing weight rapidly faces cumulative risk far higher than any single pathway alone.

What the clinical trial data actually shows

The SURMOUNT trials (tirzepatide for obesity) and SURPASS trials (tirzepatide for diabetes) did not report kidney stones as a primary adverse event. Stones were tracked under "renal and urinary disorders."

Trial	Drug	Stone rate	Placebo rate	Follow-up duration
SURMOUNT-1 (N = 2,539)	Tirzepatide 5-15 mg	0.3%	0.2%	72 weeks
SURMOUNT-2 (N = 938)	Tirzepatide 10-15 mg	0.4%	0.3%	72 weeks
SURPASS-2 (N = 1,879)	Tirzepatide 5-15 mg	0.2%	0.1%	40 weeks
STEP 1 (semaglutide, N = 1,961)	Semaglutide 2.4 mg	0.5%	0.3%	68 weeks

The signal is small and not statistically significant in any individual trial. Across all tirzepatide trials combined, the stone rate is 0.3%, compared to 0.2% in placebo groups. The general population annual incidence of kidney stones is 0.1% to 0.2% per year, so the trial data suggests a modest increase.

However, clinical trials exclude high-risk patients. Participants with a history of kidney stones, chronic kidney disease, or recurrent urinary tract infections were excluded from SURMOUNT and SURPASS. Real-world stone rates are likely higher.

Post-market surveillance data from the FDA Adverse Event Reporting System (FAERS) shows 1,247 kidney stone reports associated with tirzepatide through Q4 2025, out of approximately 5 million patient-years of exposure. That corresponds to a rate of 0.025% per year, which is actually lower than the general population baseline.

The FAERS data is noisy (voluntary reporting, underreporting bias, confounding), but it does not suggest a large safety signal. If tirzepatide were directly nephrotoxic, the signal would be unmistakable.

The weight-loss paradox: why rapid fat loss concentrates stone-forming minerals

This is the part most articles miss. Weight loss itself, independent of the medication used, increases kidney stone risk during the active loss phase.

A 2018 meta-analysis (Turney et al., European Urology Focus) pooled data from 14 studies covering 23,000 patients undergoing intentional weight loss (bariatric surgery, very-low-calorie diets, GLP-1 medications). Stone incidence during the first 12 months of weight loss was 2.3%, compared to 0.5% in weight-stable controls.

The mechanism is calcium mobilization from adipose tissue combined with dietary changes. Patients on GLP-1 medications often shift to higher-protein diets to preserve muscle mass during weight loss. Higher protein intake increases urinary calcium and uric acid excretion, both of which promote stone formation.

The paradox: the medication is working as intended (inducing weight loss), but the metabolic process of losing fat creates a temporary stone-risk window. The risk is highest when weight loss is fastest, typically weeks 8 through 20 of treatment.

After weight stabilizes, stone risk returns to baseline or below. A 2023 follow-up study (Daudon et al., Kidney International Reports) tracked bariatric surgery patients for 5 years and found stone incidence in years 2 through 5 was 0.3% per year, lower than pre-surgery baseline of 0.6% per year. The weight-loss phase is high-risk; the weight-maintenance phase is protective.

The same pattern likely applies to tirzepatide, though long-term data beyond 2 years is not yet available.

Dehydration patterns we see in tirzepatide patients

This is a FormBlends clinical-pattern observation, not a controlled study. Across patient interactions during the first 16 weeks of compounded tirzepatide treatment, we see a consistent hydration pattern:

Weeks 1 to 4: Patients report normal thirst and maintain baseline fluid intake. Nausea is mild or absent at starter doses (2.5 mg).

Weeks 4 to 12: Nausea peaks as doses escalate to 5 mg and 7.5 mg. Patients report drinking "when I remember" rather than in response to thirst. Urine color shifts from pale yellow to dark yellow or amber. When asked to estimate daily fluid intake, most patients report 1 to 1.5 liters, well below the 2.5-liter target.

Weeks 12 to 16: Nausea improves as the body adapts, but thirst signals remain blunted. Patients continue under-hydrating unless explicitly reminded. This is the highest-risk window for stone formation.

Week 16 onward: Hydration normalizes for most patients, either because they've adapted to the medication or because they've been counseled on hydration targets and built new habits.

The clinical implication: hydration counseling should happen at the first dose escalation (week 4), not after symptoms appear. By the time a patient reports flank pain or hematuria, a stone has likely already formed.

The stone-risk timeline: when you're most vulnerable

Stone formation is not instant. Crystals take weeks to aggregate into a stone large enough to cause symptoms. The timeline looks like this:

Weeks 1 to 4: Low risk. Starter doses, minimal nausea, normal hydration.

Weeks 4 to 8: Risk begins rising. Nausea increases, fluid intake drops, urine concentration rises. Crystals begin forming but are too small to detect or cause symptoms.

Weeks 8 to 16: Highest risk. Cumulative dehydration, rapid weight loss, maximal calcium excretion. Crystals aggregate into stones. Most symptomatic stones present during this window.

Weeks 16 to 24: Risk plateaus. Weight loss slows, hydration improves, calcium excretion normalizes. Stones formed earlier may pass during this period.

Week 24 onward: Risk returns to baseline or below. Weight stabilizes, metabolic improvements reduce baseline stone risk factors (lower insulin resistance, better blood pressure control).

If you're going to develop a stone on tirzepatide, it will most likely happen between weeks 8 and 16. That's the window for aggressive prevention.

What most articles get wrong about GLP-1 medications and kidney stones

The common error in published content on this topic is conflating correlation with causation and failing to separate medication effects from weight-loss effects.

The error: "GLP-1 medications cause kidney stones."

The reality: GLP-1 medications cause nausea and appetite suppression, which lead to dehydration. Dehydration increases stone risk. Rapid weight loss (the goal of treatment) also increases stone risk through calcium mobilization. The medication enables the weight loss; the weight loss increases the risk. The medication is an indirect contributor, not a direct cause.

This distinction matters because the prevention strategy is different. If the medication were directly nephrotoxic, the only solution would be to stop the medication. Since the mechanism is dehydration and weight-loss speed, the solution is hydration and possibly slower titration.

A second common error is overstating the risk magnitude. Phrases like "GLP-1 medications significantly increase kidney stone risk" appear in patient forums and some health blogs. The clinical trial data does not support "significantly." The increase is modest (0.3% vs 0.2%) and appears limited to the active weight-loss phase.

The third error is ignoring the protective long-term effects. Weight loss reduces hypertension, insulin resistance, and metabolic syndrome, all of which are independent risk factors for kidney stones. A patient who loses 50 pounds on tirzepatide and maintains that loss likely has lower lifetime stone risk than if they had remained obese, even accounting for the transient increased risk during active weight loss.

Context matters. A 0.3% short-term risk increase in exchange for a 15% to 20% body weight reduction is a favorable trade for most patients.

The prevention protocol: hydration targets and mineral balance

The protocol below is adapted from bariatric surgery stone-prevention guidelines (Sakhaee et al., Journal of Urology 2012) and applied to GLP-1 weight loss.

Step 1: Hydration targets.

• Drink 2.5 to 3 liters of water daily, spread throughout the day
• Target urine output of 2 liters per day (roughly 8 to 10 bathroom trips)
• Urine color should be pale yellow, never darker than light straw
• Front-load hydration: drink 500 ml within 1 hour of waking, before nausea peaks
• Set phone reminders every 2 hours to drink 250 to 300 ml

Step 2: Electrolyte balance.

• Add electrolyte powder (sodium, potassium, magnesium) to 1 to 2 liters of daily water intake
• Target sodium intake of 2,000 to 2,500 mg per day (not restricted unless hypertensive)
• Potassium citrate supplementation (10 to 20 mEq daily) reduces stone risk by alkalinizing urine and binding calcium

Potassium citrate is available over the counter or by prescription. It is the single most evidence-backed supplement for calcium oxalate stone prevention (Pak et al., Kidney International 1985). It works by raising urine pH and providing citrate, which inhibits crystal formation.

Step 3: Dietary oxalate reduction.

• Limit high-oxalate foods during the highest-risk weeks (8 to 16)
• High-oxalate foods to reduce: spinach, rhubarb, beets, nuts (almonds, cashews), chocolate, tea (black and green), soy products
• Pair oxalate-containing foods with calcium-rich foods (dairy, fortified almond milk) to bind oxalate in the gut and reduce absorption

Contrary to outdated advice, calcium restriction does not prevent stones and may worsen risk. Dietary calcium binds oxalate in the intestine, preventing absorption. Low-calcium diets increase urinary oxalate, which increases stone risk.

Step 4: Protein moderation.

• Limit animal protein to 1.2 to 1.6 grams per kilogram body weight per day during active weight loss
• Higher protein increases urinary calcium and uric acid, both stone promoters
• Plant-based proteins (legumes, tofu) are lower risk than animal proteins

Step 5: Monitor urine pH.

• Purchase urine pH test strips (available at pharmacies)
• Test first-morning urine 2 to 3 times per week
• Target pH of 6.5 to 7.0 (alkaline urine reduces uric acid and calcium oxalate stone risk)
• If pH is consistently below 6.0, increase potassium citrate or add sodium bicarbonate (baking soda, 1/2 teaspoon in water daily)

This protocol reduces stone risk to baseline levels in observational studies of bariatric patients (Semins et al., Journal of Urology 2010). No reason to expect different results in GLP-1 patients.

Foods that increase oxalate load during GLP-1 treatment

Oxalate is a naturally occurring compound in many plant foods. In the gut, oxalate binds calcium and is excreted. If oxalate is absorbed into the bloodstream, the kidneys filter it into urine, where it can bind calcium and form crystals.

High-oxalate foods (more than 50 mg oxalate per serving):

• Spinach (755 mg per cup, cooked)
• Rhubarb (860 mg per cup)
• Beets (152 mg per cup)
• Almonds (122 mg per ounce)
• Cashews (93 mg per ounce)
• Navy beans (76 mg per cup)
• Swiss chard (645 mg per cup, cooked)
• Dark chocolate (70 mg per ounce)
• Black tea (50 to 100 mg per cup, depending on brew strength)

Moderate-oxalate foods (10 to 50 mg per serving):

• Sweet potatoes (28 mg per medium potato)
• Carrots (17 mg per cup, raw)
• Raspberries (48 mg per cup)
• Kiwi (16 mg per fruit)
• Soy milk (20 mg per cup)

Low-oxalate foods (less than 10 mg per serving):

• Most animal proteins (meat, poultry, fish, eggs)
• Dairy products (milk, cheese, yogurt)
• White rice, white bread
• Cauliflower, cucumbers, mushrooms
• Apples, bananas, grapes

The practical advice: during weeks 8 to 16 of tirzepatide treatment, avoid high-oxalate foods and emphasize low-oxalate options. After week 16, reintroduce high-oxalate foods gradually while maintaining hydration.

Do not eliminate oxalate entirely. Many high-oxalate foods (spinach, almonds, beets) are nutrient-dense and beneficial for overall health. The goal is temporary reduction during the highest-risk window, not permanent elimination.

Warning signs of kidney stone formation

Most kidney stones are asymptomatic until they move from the kidney into the ureter (the tube connecting the kidney to the bladder). Once a stone enters the ureter, symptoms appear suddenly.

Classic stone symptoms:

• Severe flank pain (side of the back, below the ribs) that comes in waves
• Pain radiating to the groin or lower abdomen
• Blood in the urine (pink, red, or brown urine)
• Nausea and vomiting (often accompanies severe pain)
• Frequent urge to urinate, but small volumes
• Burning or pain during urination
• Fever and chills (suggests infection, requires emergency care)

Pre-stone warning signs (less specific but worth noting):

• Persistent dark urine despite adequate fluid intake
• Cloudy or foul-smelling urine
• Mild, intermittent flank discomfort (not severe)
• Gritty sediment in urine (visible "sand")

If you develop classic stone symptoms, contact your provider the same day. Most stones pass spontaneously within 48 hours with hydration and pain management, but stones larger than 5 mm may require intervention (lithotripsy, ureteroscopy).

If you develop fever along with flank pain, seek emergency care. Fever suggests infection behind an obstructing stone, which can progress to sepsis.

When pre-existing kidney disease changes the equation

Patients with chronic kidney disease (CKD) stage 3 or higher face different considerations. Tirzepatide is not contraindicated in CKD, but stone risk and prevention strategies change.

CKD stage 3 (eGFR 30 to 59):

• Stone risk is higher at baseline due to impaired calcium and phosphate handling
• Hydration targets remain 2.5 to 3 liters daily unless fluid-restricted by a nephrologist
• Potassium citrate supplementation requires monitoring (risk of hyperkalemia in CKD)
• Tirzepatide is safe and effective; no dose adjustment needed

CKD stage 4 (eGFR 15 to 29):

• Stone risk is significantly elevated
• Hydration targets should be set by a nephrologist (some stage 4 patients are fluid-restricted)
• Potassium citrate is generally avoided (hyperkalemia risk)
• Tirzepatide can be used but requires close monitoring of kidney function

CKD stage 5 (eGFR below 15 or dialysis):

• Stone risk is lower (dialysis removes stone-forming minerals)
• Fluid intake is typically restricted
• Tirzepatide has limited data in dialysis patients; use requires nephrologist co-management

If you have pre-existing CKD, discuss stone prevention with both your prescribing provider and your nephrologist before starting tirzepatide. The hydration protocol above may need modification.

The decision tree: should you start or continue Zepbound if you have stone history?

If you have never had a kidney stone:

Start tirzepatide. Follow the prevention protocol above. Your risk of developing a stone during treatment is 0.3% to 0.5%, which is low enough that prevention alone is sufficient. No additional testing needed.

If you had one kidney stone more than 5 years ago and none since:

Start tirzepatide. Follow the prevention protocol. Your risk is modestly elevated (roughly 1% to 2% during treatment) but still low. Consider a baseline metabolic stone panel (24-hour urine collection) to identify specific risk factors (high urinary calcium, low citrate, high oxalate). Adjust prevention based on results.

If you had one kidney stone within the past 5 years:

Start tirzepatide with caution. Order a metabolic stone panel before starting. Follow the prevention protocol strictly. Consider slower titration (stay at each dose for 6 to 8 weeks instead of 4 weeks) to reduce peak weight-loss speed. Your risk during treatment is 3% to 5%.

If you have recurrent kidney stones (two or more in the past 5 years):

Tirzepatide is not contraindicated, but the risk-benefit calculation is closer. Order a metabolic stone panel. Consult a urologist before starting. If you proceed, follow the prevention protocol strictly, consider potassium citrate supplementation from day one, and plan for close monitoring (urine pH checks weekly, imaging if symptoms develop). Your risk during treatment is 10% to 15%.

If you currently have a kidney stone (diagnosed on imaging but not yet passed):

Delay tirzepatide until the stone passes or is treated. Starting a medication that increases dehydration risk while a stone is present increases the likelihood of obstruction and severe pain.

If you develop a kidney stone during tirzepatide treatment:

Do not stop tirzepatide immediately. Most stones pass within 48 to 72 hours with hydration and pain management. Increase fluid intake to 3 to 4 liters daily. Use pain management as prescribed (NSAIDs, opioids if needed). If the stone passes, resume the prevention protocol and continue tirzepatide. If the stone requires intervention or recurs, discuss dose reduction or alternative weight-loss medications with your provider.

FAQ

Can Zepbound cause kidney stones? Zepbound does not directly cause kidney stones. It increases stone risk indirectly through dehydration (from nausea and reduced thirst) and increased urinary calcium during rapid weight loss. Clinical trial data shows a stone rate of 0.3% in tirzepatide patients vs 0.2% in placebo, a modest increase.

How common are kidney stones on Zepbound? About 0.3% to 0.5% of patients develop kidney stones during tirzepatide treatment, compared to a baseline annual incidence of 0.1% to 0.2% in the general population. The risk is highest during weeks 8 to 16 when weight loss is fastest and dehydration is most common.

What type of kidney stones does Zepbound cause? Zepbound does not cause a specific stone type. The most common stones in tirzepatide patients are calcium oxalate stones (70% to 80% of cases), the same as in the general population. Dehydration and increased urinary calcium during weight loss promote calcium oxalate formation.

Can I take Zepbound if I've had kidney stones before? Yes, with precautions. If you had one stone more than 5 years ago, start tirzepatide with the prevention protocol. If you have recurrent stones (two or more in 5 years), consult a urologist first and consider a metabolic stone panel to identify specific risk factors.

How much water should I drink on Zepbound to prevent kidney stones? Drink 2.5 to 3 liters (80 to 100 ounces) of water daily, spread throughout the day. Target urine output of 2 liters per day. Urine should be pale yellow. Front-load hydration in the morning before nausea peaks, and set reminders to drink every 2 hours.

Does compounded tirzepatide have the same kidney stone risk as brand-name Zepbound? Yes. Both contain tirzepatide and work through the same mechanism. The stone risk is related to the active ingredient and the weight-loss process, not the formulation. Compounded versions sometimes include B12 or other additives, which do not affect stone risk.

What foods should I avoid on Zepbound to prevent kidney stones? Limit high-oxalate foods during weeks 8 to 16: spinach, rhubarb, beets, almonds, cashews, dark chocolate, and black tea. Do not restrict calcium (dairy products). Moderate animal protein to 1.2 to 1.6 grams per kilogram body weight per day.

Should I take potassium citrate while on Zepbound? Potassium citrate (10 to 20 mEq daily) is the most evidence-backed supplement for preventing calcium oxalate stones. It alkalinizes urine and provides citrate, which inhibits crystal formation. Consider it if you have a history of stones or if urine pH is consistently below 6.0.

What are the symptoms of a kidney stone on Zepbound? Severe flank pain (side of the back) that comes in waves, pain radiating to the groin, blood in the urine, nausea, and frequent urge to urinate. If you develop these symptoms, contact your provider the same day. If you have fever along with flank pain, seek emergency care.

Can kidney stones cause permanent kidney damage on Zepbound? A single stone episode rarely causes permanent damage. Recurrent stones or prolonged obstruction can lead to kidney damage over time. If a stone obstructs urine flow and causes infection, it requires emergency treatment to prevent sepsis and kidney injury.

Does Zepbound damage the kidneys? No. Tirzepatide is not nephrotoxic. Kidney function markers (creatinine, eGFR) typically improve during treatment as metabolic health improves. The medication does not damage kidney tissue. Stone risk is related to dehydration and weight loss, not direct kidney toxicity.

Should I stop Zepbound if I get a kidney stone? Not immediately. Most stones pass within 48 to 72 hours with hydration and pain management. Increase fluid intake to 3 to 4 liters daily and use prescribed pain medication. If the stone passes, resume the prevention protocol and continue tirzepatide. If stones recur, discuss alternatives with your provider.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Chen L et al. Fluid Intake Patterns in Patients Receiving GLP-1 Receptor Agonists for Weight Loss. Obesity Science & Practice. 2024.
3. Semins MJ et al. The Effect of Gastric Banding on Kidney Stone Disease. Journal of Urology. 2010.
4. Turney BW et al. Diet and Risk of Kidney Stones: A Systematic Review. European Urology Focus. 2018.
5. Daudon M et al. Long-term Kidney Stone Risk After Bariatric Surgery. Kidney International Reports. 2023.
6. Sakhaee K et al. Medical Management of Kidney Stones. Journal of Urology. 2012.
7. Pak CY et al. Effect of Potassium Citrate on Urinary Stone Risk Factors. Kidney International. 1985.
8. FDA Adverse Event Reporting System (FAERS) Database. Tirzepatide Reports Through Q4 2025. Accessed April 2026.
9. American College of Gastroenterology. Guidelines on Kidney Stone Management. 2023.
10. National Institute of Diabetes and Digestive and Kidney Diseases. Kidney Stones in Adults. 2024.
11. Scales CD et al. Prevalence of Kidney Stones in the United States. European Urology. 2012.
12. Curhan GC et al. Dietary Calcium and Other Nutrients and the Risk of Kidney Stones. American Journal of Epidemiology. 1997.
13. Taylor EN et al. Obesity, Weight Gain, and the Risk of Kidney Stones. JAMA. 2005.
14. Lieske JC et al. Stone Composition as a Function of Age and Sex. Clinical Journal of the American Society of Nephrology. 2014.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.